<DOC>
	<DOCNO>NCT01663740</DOCNO>
	<brief_summary>This observational study compare spermatogenesis male adult renal transp lant recipient receive valganciclovir versus untreated matched control . Data collect patient 52 week post transplant .</brief_summary>
	<brief_title>An Observational Study Spermatogenesis Male Renal Transplant Recipients Receiving Valcyte ( Valganciclovir ) Versus Untreated Matched Controls</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<criteria>Male patient , &gt; /= 20 &lt; /= 50 year age First renal transplant Patient eligible receive least 100 day 200 day valganciclovir prophylaxis determined treat physician accordance product information ( Cohort A ) patient expect require valganciclovir prophylaxis ( Cohort B ) posttransplant Patient history know infertility Patient willing provide sperm sample Patient agree use barrier contraceptive throughout study least 90 day cessation valganciclovir treatment Prior ganciclovir valganciclovir within 3 month enrollment Organ transplant kidney Has receive investigational new drug 3 month prior transplant Receiving alkylating agent medication know affect spermatogenesis</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>